Is BMY.SW stock a buy after the intraday drop?

For short-term traders the dip offers a bounce trade to the 50-day average at CHF43.75. For longer-term investors, weigh Meyka AI’s one-year forecast of CHF39.34 and the company’s leverage and pipeline risks before buying.

What are short-term targets and stops for BMY.SW stock?

Target **CHF43.75** as the first exit, **CHF44.50** as a secondary target, and **CHF46.00** for a stretch. Use a stop near **CHF41.00** to control downside on an intraday bounce trade.

Which fundamentals matter most for BMY.SW stock now?

Watch EPS **2.66**, PE near **15.99**, free cash flow yield **23.53%**, dividend yield **3.50%**, and debt-to-equity **2.75**. These drive valuation sensitivity around earnings and pipeline news.

How does sector performance affect BMY.SW stock?

Healthcare momentum is generally positive, which supports a reversion trade. However, company-specific news and patent timelines can override sector trends and increase volatility for BMY.SW stock.

CH Stocks

CHF42.54 drop for Bristol-Myers Squibb BMY.SW (SIX) 02 Mar 2026: bounce setup

ByHuzaifa Zahoor March 2, 2026March 2, 2026

We see an intraday drop to CHF42.54 for Bristol-Myers Squibb Company (BMY.SW) on the SIX exchange, down -4.40% from the previous close. The pullback is steep and executed on a high relative volume of 22.73x the average, creating a classic oversold bounce set-up. Traders can watch a short-term mean-reversion toward the 50-day average at CHF43.75 while monitoring liquidity and debt metrics. We present a clear trade plan, valuation context, and risk points for an intraday bounce strategy on BMY.SW stock.